Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel inhibitors of hepatitis C virus replication

An alkyl and compound technology, applied in the field of compounds for the treatment of hepatitis C virus infection, can solve the problems of treatment failure and patients without treatment alternatives, etc.

Inactive Publication Date: 2009-07-29
INTERMUNE INC +1
View PDF63 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, even with combination therapy using pegylated IFN-alpha plus ribavirin, 40% to 50% of patients fail treatment as non-responders or relapsers
There are currently no effective therapeutic alternatives for these patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel inhibitors of hepatitis C virus replication
  • Novel inhibitors of hepatitis C virus replication
  • Novel inhibitors of hepatitis C virus replication

Examples

Experimental program
Comparison scheme
Effect test

example A

[0552] Example A : NS3-NS4 protease assay

[0553] NS3 complex formation with NS4A-2

[0554] Recombinant E. coli or baculovirus full-length NS3 was diluted to 3.33 μΜ with assay buffer and the material was transferred to an eppendorf tube and placed in a water bath in a 4°C refrigerator. Add an appropriate amount of NS4A-2 up to 8.3 mM in assay buffer to equal the volume of NS3 in step 2.1.1 (conversion factor - 3.8 mg / 272 μL assay buffer). The material was transferred to an Eppendorf tube and placed in a water bath in a 4°C refrigerator.

[0555] After equilibrating at 4°C, equal volumes of NS3 and NS4A-2 solutions were combined in Eppendorf tubes, mixed gently with a manual pipette, and the mixture was incubated in a 4°C water bath for 15 minutes. The final concentrations in the mixture were 1.67 [mu]M NS3, 4.15 mM NS4A-2 (2485-fold molar excess of NS4A-2).

[0556] After 15 minutes at 4°C, the NS3 / NS4A-2 Eppendorf tubes were removed and placed in a room temperature wa...

example B

[0557] Example B : NS3 Inhibition Assay

[0558] Sample compounds were dissolved in DMSO up to 10 mM and then diluted to 2.5 mM in DMSO (1:4). Compounds are typically added to assay plates at a concentration of 2.5 mM and diluted to give a starting concentration of 50 [mu]M in the assay inhibition curve. Compounds were serially diluted in assay buffer to provide lower concentrations of test solutions.

[0559] E. coli NS3 / NS4A-2 was diluted to 4 nM NS3 (1:417.5 of 1.67 μM stock - 18 μL of 1.67 μM stock + 7497 μL assay buffer). BV NS3 / NS4A-2 was diluted to 6 nM NS3 (1:278.3 of 1.67 μM stock - 24 μL of 1.67 μM stock + 6655 μL assay buffer). Using a manual multichannel pipette, being careful not to introduce air bubbles into the plate, 50 μL of assay buffer was added to wells A01-H01 of a black Costar 96-well polypropylene storage plate.

[0560] Using a manual multichannel pipette, being careful not to introduce air bubbles into the plate, add 50 µL of the diluted NS3 / NS4A-...

example

[0574] table 3

[0575] compound

NS3-NS4 IC 50

90

D

91

C

101

A

102

B

103

B

104

A

105

A

106

A

107

A

108

B

109

A

110

B

111

A

112

B

[0576] where A indicates an IC between 10 and 50 μM 50 , B indicates IC between 1 and 10 μM 50 , C represents an IC between 0.1 and 1 μM 50 , and D represents an IC of less than 0.1 μM 50 .

[0577] in conclusion

[0578] Potent small molecule inhibitors of the HCV NS3 protease have been developed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
hydrogen bond lengthaaaaaaaaaa
body surface areaaaaaaaaaaa
Login to View More

Abstract

The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula (III), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Description

[0001] Related applications [0002] This application claims the benefit of U.S. Provisional Application No. 60 / 819,128, filed July 6, 2006, and U.S. Provisional Application No. 60 / 818,914, filed July 5, 2006, both of which are incorporated by reference in their entirety. into this article. technical field [0003] The present invention relates to compounds, methods of synthesis, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Background technique [0004] Hepatitis C virus (HCV) infection is the most common chronic blood-borne infection in the United States. Although the number of new infections has declined, the burden of chronic infection remains substantial, with the Centers for Disease Control estimating that 3,900,000 (1.8%) are infected in the United States. Chronic liver disease is the tenth leading cause of death among US adults and is responsible for approximately 25,000 deaths each year, or approximately 1% of all deaths. Studi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D231/56C07D403/14C07D471/04A61K31/4035A61K31/416A61K31/437A61P31/14
Inventor 劳伦斯·M·布拉特斯科特·塞韦特利奥尼德·拜格尔曼蒂莫西·克尔彻阿普里尔·L·肯尼迪史蒂文·W·安德鲁斯
Owner INTERMUNE INC